World

Omicron significantly reduces Covid antibody protection in a small study of Pfizer vaccine recipients

Nurse Mary Ezzat will administer Pfizer COVID-19 booster shots to Jessica M. at the UCI Medical Center in Orange, California, on Thursday, August 19, 2021.

Jeff Gritchen | MediaNews Group | Orange County Register via Getty Images

According to South African scientists, the Omicroncovid variant significantly reduces the antibodies produced by the Pfizer and BioNTech vaccines, but those who recovered from the virus and received booster shots were announced Tuesday. According to a small preliminary study, protection from severe illness is likely to be enhanced.

Professor Alex Sigal and a team of scientists at the African Institute of Health tested blood samples from 12 people previously vaccinated with the Pfizer / BioNTech vaccine, and how well the vaccine-generated antibodies neutralize new variants. I specifically investigated whether it could be done. It means blocking the ability to infect cells.

According to the study’s preprints, they have a 41-fold reduction in the ability of the antibody to neutralize the Omicron mutant compared to the original virus, dramatically reducing performance against the original ancestral strain and other mutants. I found that. Not yet peer reviewed. Vaccine-induced antibodies have tripled the ability to neutralize early beta mutants that previously dominated South Africa, suggesting that Omicron is far superior to evading defense.

“The results presented here at Omicron show a much broader escape than the beta version,” the researchers write. “Previous infections followed by vaccination or boosting may increase neutralization levels and provide protection from the serious illness of Omicron infections.”

The preprint study has not yet been peer-reviewed and tested 14 plasma samples from 12 vaccinated people. Six of them were previously infected. Due to the urgency of the pandemic, scientists are making Covid’s research available before going through an extensive peer-review process.

Pfizer CEO Albert Bourla said Friday that he could develop a vaccine that specifically targets Omicron by March 2022, if necessary. Bourla said it would take weeks to get clearer data on whether current vaccines provide adequate protection against mutants.

Pfizer’s CEO had previously told CNBC that the protection provided by the company’s double-dose vaccine could be partially diminished in the face of Omicron.

South African scientists have also discovered that Omicron attaches to the same protein and infects the human lung cells used by previous variants.

This is a developing story. Please check for updates.

Omicron significantly reduces Covid antibody protection in a small study of Pfizer vaccine recipients

Source link Omicron significantly reduces Covid antibody protection in a small study of Pfizer vaccine recipients

Back to top button